

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATUTORY FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022

2024A3/nor

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES

Toh Puan Dato' Seri Hajjah Dr Aishah Ong
Lim Siew Lian
Alan Hamzah Sendut
Tan Sri Dato' Dr Ir Gan Thian Leong
Dato' Leong Kwei Chun
Datuk Professor Dr. Looi Lai Meng
Ahmad Redza Bin Abdul Wahab
Wong Lup Hang
Dr Hajjah Yatela binti Zainal Abidin
Tunku Ali Redhauddin Ibni Tunku Muhriz (Appointed on 21 March 2022)
Tengku Datuk Seri Ahmad Shah Al-Haj ibni Almarhum Sultan Salahuddin
Abdul Aziz Shah Al-Haj (Resigned on 1 March 2022)

SECRETARIES

Chua Siew Chuan
Chin Mun Yee
Tan Loo Ee

AUDITORS

PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146)
Chartered Accountants

REGISTERED OFFICE

Level 7, Menara Milenium
Jalan Damanlela, Pusat Bandar Damansara
Damansara Height
50490 Kuala Lumpur
Wilayah Persekutuan

PRINCIPAL PLACE OF BUSINESS

2nd Floor, Outpatient Centre
Sime Darby Medical Centre Subang Jaya
47500 Subang Jaya
Selangor Darul Ehsan
Malaysia

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

CONTENTS	PAGE(S)
TRUSTEES' REPORT	1 - 4
INCOME AND EXPENDITURE STATEMENTS	5
STATEMENTS OF FINANCIAL POSITION	6
STATEMENTS OF CHANGES IN GENERAL FUNDS	7
STATEMENTS OF CASH FLOWS	8 - 10
NOTES TO THE FINANCIAL STATEMENTS	11 - 31
STATEMENT BY TRUSTEES	32
STATUTORY DECLARATION	32
INDEPENDENT AUDITORS' REPORT	33 - 36

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT

The Trustees are pleased to submit their report together with the audited financial statements of the Group and of the Foundation for the financial year ended 31 December 2022.

PRINCIPAL ACTIVITY

The principal activity of the Foundation is to receive and administer funds for cancer research purposes. There have been no significant changes in the nature of this activity during the financial year.

The Foundation is incorporated in Malaysia as a company limited by guarantee and does not have a share capital.

On 24 September 2021, the Foundation incorporated a wholly-owned subsidiary known as CRM Technology Sdn. Bhd., a company incorporated in Malaysia with a share capital of RM100.

The principal activity of the subsidiary is stated in Note 8 of the financial statements. .

FINANCIAL RESULTS

	<u>Group</u> RM	<u>Foundation</u> RM
Excess of income over expenditure for the financial year	<u>6,764,419</u>	<u>6,772,080</u>

RESERVES AND PROVISIONS

There were no material transfers to or from reserves and provisions during the financial year.

BOARD OF TRUSTEES

The members of the Board of Trustees in office during the financial year and from the end of the financial year to the date of the report are:

Toh Puan Dato' Seri Hajjah Dr Aishah Ong
Lim Siew Lian
Alan Hamzah Sendut
Tan Sri Dato' Dr Ir Gan Thian Leong
Dato' Leong Kwei Chun
Datuk Professor Dr. Looi Lai Meng
Ahmad Redza Bin Abdul Wahab
Wong Lup Hang
Dr Hajjah Yatela binti Zainal Abidin
Tunku Ali Redhaudhin Ibni Tunku Muhriz (Appointed on 21 March 2022)
Tengku Datuk Seri Ahmad Shah Al-Haj ibni Almarhum Sultan Salahuddin Abdul Aziz Shah Al-Haj
(Resigned on 1 March 2022)

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

TRUSTEES' BENEFITS

Since the end of the previous financial year, no Trustee has received or become entitled to receive a benefit by reason of a contract made by the Group and the Foundation or a related corporation with the Trustee or with a firm of which the Trustee is a member, or with a company in which the Trustee has a substantial financial interest.

During and at the end of the financial year, no arrangements subsisted to which the Group and the Foundation is a party, being arrangements with the object or objects of enabling the Trustees of the Foundation to acquire benefits by means of the acquisition of shares in, or debentures of, the Foundation or any other body corporate.

No trustee has received any remuneration during the financial year.

STATUTORY INFORMATION ON THE FINANCIAL STATEMENTS

Before the financial statements of the Group and of the Foundation were prepared, the Trustees took reasonable steps:

- (a) to ascertain that proper action had been taken in relation to the writing off of bad debts and the making of allowance for doubtful debts and satisfied themselves that all known bad debts had been written off and that adequate allowance had been made for doubtful debts; and
- (b) to ensure that any current assets, which were unlikely to realise in the ordinary course of business including the values of current assets as shown in the accounting records of the Group and of the Foundation, have been written down to an amount which the current assets might be expected so to realise.

At the date of this report, the Trustees are not aware of any circumstances:

- (a) which would render the amounts written off for bad debts or the amount of allowance for doubtful debts in the financial statements of the Group and of the Foundation inadequate to any substantial extent; or
- (b) which would render the values attributed to current assets in the financial statements of the Group and of the Foundation misleading; or
- (c) which have arisen which render adherence to the existing method of valuation of assets or liabilities of the Group and of the Foundation misleading or inappropriate.

No contingent or other liability has become enforceable or is likely to become enforceable within the period of twelve months after the end of the financial year which, in the opinion of the Trustees, will or may substantially affect the ability of the Foundation and its subsidiary to meet their obligations when they fall due.

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

STATUTORY INFORMATION ON THE FINANCIAL STATEMENTS (CONTINUED)

At the date of this report, there does not exist:

- (a) any charge on the assets of the Group and of the Foundation which has arisen since the end of the financial year which secures the liability of any other person; or
- (b) any contingent liability of the Group and of the Foundation which has arisen since the end of the financial year.

At the date of this report, the Trustees are not aware of any circumstances not otherwise dealt with in this report or the financial statements which would render any amount stated in the financial statements misleading.

In the opinion of the Trustees:

- (a) the results of the Group and of the Foundation's operations during the financial year were not substantially affected by any item, transaction or event of a material and unusual nature; and
- (b) there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature that is likely to affect substantially the results of the operations of the Group and of the Foundation for the financial year in which this report is made.

AUDITORS' REMUNERATION

The amount paid or payable as remuneration of the auditors of the Company for the financial year ended 31 December 2022 is as follows:

	RM
Auditor's remuneration	<u>5,000</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

AUDITORS

The auditors, PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146), have expressed their willingness to continue in office.

This report was approved by the Board of Trustees on 8 June 2023. Signed on behalf of the Board of Trustees:



TOH PUAN DATO' SERI HAJJAH
DR AISHAH ONG

TRUSTEE

Kuala Lumpur



ALAN HAMZAH SENDUT

TRUSTEE

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**INCOME AND EXPENDITURE STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022**

	Note	Group		Foundation	
		2022 RM	2021 RM	2022 RM	2021 RM
INCOME					
Donations		13,902,039	4,133,836	13,902,039	4,133,836
Research grants		1,236,817	758,148	1,236,817	758,148
Other income		4,477	43,013	4,477	43,013
Interest income		363,266	335,995	363,266	335,995
		<u>15,506,599</u>	<u>5,270,992</u>	<u>15,506,599</u>	<u>5,270,992</u>
LESS: EXPENDITURE					
Staff costs	4	(5,694,987)	(4,795,325)	(5,694,987)	(4,795,325)
Research expenditure		(661,318)	(523,632)	(661,318)	(523,632)
Depreciation of property, plant and equipment	6	(585,419)	(502,588)	(585,419)	(502,588)
Depreciation of right-of-use asset	7	(90,330)	(93,909)	(90,330)	(93,909)
(Loss)/gain on disposal of property, plant and equipment		(13,158)	11,098	(13,158)	11,098
Write-off of property, plant and equipment		-	(1,466)	-	(1,466)
Reversal of impairment/ (impairment) of financial assets	9	212,562	(221,358)	212,562	(221,358)
Training expenditure		(61,741)	(6,821)	(61,741)	(6,821)
Repairs and maintenance expenditure		(6,943)	(28,588)	(6,943)	(28,588)
Professional fees		(176,081)	(120,724)	(168,706)	(120,724)
Travelling expenses		(113,852)	(14,505)	(113,852)	(14,505)
Computer related expenses		(226,629)	(153,402)	(226,629)	(153,402)
Insurance expenses		(24,587)	(78,805)	(24,587)	(78,805)
Marketing and fund raising expenses		(182,215)	(3,871)	(182,215)	(3,871)
Laboratory maintenance		(27,922)	(120,419)	(27,922)	(120,419)
Rental		(78,526)	(34,778)	(78,526)	(34,778)
Utilities		(57,185)	(3,131)	(57,185)	(3,131)
Purchased services		(392,485)	(169,780)	(392,485)	(169,780)
Dues and subscriptions		(15,749)	(4,255)	(15,749)	(4,255)
Interest expense on lease liability	11	(2,613)	(5,666)	(2,613)	(5,666)
Other expenses		(543,002)	(387,497)	(542,716)	(387,497)
		<u>(8,742,180)</u>	<u>(7,259,422)</u>	<u>(8,734,519)</u>	<u>(7,259,422)</u>
EXCESS OF INCOME OVER EXPENDITURE/ (EXPENDITURE OVER INCOME)		<u>6,764,419</u>	<u>(1,988,430)</u>	<u>6,772,080</u>	<u>(1,988,430)</u>

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATEMENTS OF FINANCIAL POSITION
AS AT 31 DECEMBER 2022

	Note	Group		Foundation	
		2022 RM	2021 RM	2022 RM	2021 RM
GENERAL FUNDS					
Balance at beginning of the financial year		18,050,849	20,039,279	18,050,849	20,039,279
Excess of income over expenditure/ (expenditure over income)		6,764,419	(1,988,430)	6,772,080	(1,988,430)
Balance at end of the financial year		<u>24,815,268</u>	<u>18,050,849</u>	<u>24,822,929</u>	<u>18,050,849</u>
Represented by:					
NON-CURRENT ASSETS					
Property, plant and equipment	6	3,322,870	1,593,004	3,322,870	1,593,004
Right-of-use asset	7	15,056	105,386	15,056	105,386
Investment in a subsidiary	8	-	-	100	100
		<u>3,337,926</u>	<u>1,698,390</u>	<u>3,338,026</u>	<u>1,698,490</u>
CURRENT ASSETS					
Receivables	9	2,450,160	659,545	2,450,160	659,545
Amount due from subsidiary		-	-	6,325	-
Deposits, cash and bank balances	10	19,829,899	15,828,678	19,829,185	15,828,678
		<u>22,280,059</u>	<u>16,488,223</u>	<u>22,285,670</u>	<u>16,488,223</u>
NON-CURRENT LIABILITY					
Lease liability	11	-	13,982	-	13,982
LESS: CURRENT LIABILITY					
Lease liability	11	16,595	100,035	16,595	100,035
Amount due to a subsidiary		-	-	100	100
Payables	12	786,122	21,747	784,072	21,747
		<u>802,717</u>	<u>121,782</u>	<u>800,767</u>	<u>121,882</u>
TOTAL LIABILITIES		<u>802,717</u>	<u>135,764</u>	<u>800,767</u>	<u>135,864</u>
NET CURRENT ASSETS		<u>21,477,342</u>	<u>16,366,441</u>	<u>21,484,903</u>	<u>16,366,341</u>
NET ASSETS		<u>24,815,268</u>	<u>18,050,849</u>	<u>24,822,929</u>	<u>18,050,849</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**STATEMENTS OF CHANGES IN GENERAL FUNDS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022**

	<u>Note</u>	<u>Group</u>		<u>Foundation</u>	
		<u>2022</u> RM	<u>2021</u> RM	<u>2022</u> RM	<u>2021</u> RM
As at 1 January		18,050,849	20,039,279	18,050,849	20,039,279
Excess of income over expenditure/ (expenditure over income)		<u>6,764,419</u>	<u>(1,988,430)</u>	<u>6,772,080</u>	<u>(1,988,430)</u>
As at 31 December		<u><u>24,815,268</u></u>	<u><u>18,050,849</u></u>	<u><u>24,822,929</u></u>	<u><u>18,050,849</u></u>

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022

	Note	Group		Foundation	
		2022 RM	2021 RM	2022 RM	2021 RM
OPERATING ACTIVITIES					
Excess of income over expenditure/ (expenditure over income)		6,764,419	(1,988,430)	6,772,080	(1,988,430)
Adjustments for:					
Property, plant and equipment					
- depreciation		585,419	502,588	585,419	502,588
- write-off		-	1,466	-	1,466
- loss/(gain) on disposal		13,158	(11,098)	13,158	(11,098)
Depreciation of right-of-use asset		90,330	93,909	90,330	93,909
Impairment of financial assets		(212,562)	221,358	(212,562)	221,358
Interest expense on lease liability		2,613	5,666	2,613	5,666
Interest income		(363,266)	(335,995)	(363,266)	(335,995)
		6,880,111	(1,510,536)	6,887,772	(1,510,536)
Changes in working capital:					
Receivables		(1,529,427)	1,789,618	(1,529,427)	1,789,618
Payables		227,172	(152,548)	225,122	(152,548)
Net cash flows generated from operating activities		5,577,856	126,534	5,583,467	126,534
INVESTING ACTIVITIES					
Purchase of property, plant and equipment	6	(1,837,731)	(161,627)	(1,837,731)	(161,627)
Proceeds from disposal of property, plant and equipment		46,491	11,098	46,491	11,098
Interest income received		314,640	249,449	314,640	249,449
Advances to subsidiary		-	-	(6,325)	-
Increase in bank deposits maturing more than three months		(2,020,000)	(13,330,000)	(2,020,000)	(13,330,000)
Net cash flows used in investing activities		(3,496,600)	(13,231,080)	(3,502,925)	(13,231,080)
FINANCING ACTIVITY					
Payment of lease liability		(100,035)	(98,637)	(100,035)	(98,637)
Net cash flow used in financing activity		(100,035)	(98,637)	(100,035)	(98,637)

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

	<u>Note</u>	<u>Group</u>		<u>Foundation</u>	
		<u>2022</u> RM	<u>2021</u> RM	<u>2022</u> RM	<u>2021</u> RM
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS		1,981,221	(13,203,183)	1,980,507	(13,203,183)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL YEAR		<u>948,678</u>	<u>14,151,861</u>	<u>948,678</u>	<u>14,151,861</u>
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL YEAR	10	<u><u>2,929,899</u></u>	<u><u>948,678</u></u>	<u><u>2,929,185</u></u>	<u><u>948,678</u></u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company limited by guarantee and not having a share capital)

**STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)**

Cash flows and non-cash changes in liability arising from financing activity are as follows:

<u>Group/Foundation</u>	<u>At 1 January</u> RM	<u>Repayment</u> RM	<u>Non-cash changes</u>			<u>At 31 December</u> RM
			<u>Interest expense</u> RM	<u>Lease addition</u> RM	<u>Lease modification/ (termination)</u> RM	
<u>2022</u>						
Lease liability	114,017	(100,035)	2,613	-	16,595	
	<u>114,017</u>	<u>(100,035)</u>	<u>2,613</u>	<u>-</u>	<u>16,595</u>	
<u>2021</u>						
Lease liability	132,848	(98,637)	5,666	74,140	114,017	
	<u>132,848</u>	<u>(98,637)</u>	<u>5,666</u>	<u>74,140</u>	<u>114,017</u>	

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022

1 GENERAL INFORMATION

The Foundation is a company incorporated and domiciled in Malaysia, limited by guarantee and does not have a share capital. The registered office of the Foundation is located at Level 7, Menara Milenium, Jalan Damanlela, Pusat Bandar Damansara, Damansara Heights, 50490 Kuala Lumpur, Wilayah Persekutuan and the principal place of business of the Foundation is located at 2nd Floor, Outpatient Centre, Sime Darby Medical Centre Subang Jaya, 47500 Subang Jaya, Selangor Darul Ehsan.

The principal activity of the Foundation is to receive and administer funds for cancer research purposes. There have been no significant changes in the nature of this activity during the financial year.

The financial statements were authorised for issue by the Board of Trustees in accordance with a resolution dated 8 June 2023.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A BASIS OF PREPARATION

The financial statements of the Group and of the Foundation have been prepared in accordance with the provisions of the Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

The financial statements have been prepared under the historical cost convention except as disclosed in this summary of significant accounting policies.

The preparation of financial statements in conformity with MFRS requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses during the reported period. It also requires the Trustees to exercise their judgement in the process of applying the Group's and Foundation's accounting policies. Although these estimates and judgement are based on the Trustees' best knowledge of current events and actions, actual results may differ.

The Foundation has prepared consolidated financial statements subsequent to the incorporation of its wholly-owned subsidiary known as indicated in Note 8 of the financial statements.

The Trustees are of the view that there were no critical accounting estimates and assumptions which would have a material impact to the Group and Foundation's income and expenditure and financial position or accounting policies that require subjective judgement in the current financial year.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

A BASIS OF PREPARATION (continued)

(a) Accounting pronouncements that are effective and have been adopted by the Group and the Foundation as at 1 January 2022:

- Amendments to MFRS 16 'Covid-19-Related Rent Concessions'
- Interest Rate Benchmark Reform—Phase 2 - Amendments to MFRS 9, MFRS 139, MFRS 7, MFRS 4 and MFRS 16

The amendments listed above did not have significant impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

(b) Accounting pronouncements that are not yet effective and have not been early adopted by the Group and the Foundation:

Accounting pronouncements that are currently being assessed by the Trustees:

Effective for annual periods beginning on or after 1 January 2023

- Amendments to MFRS 101 and MFRS Practice Statement 2 and MFRS 108 on disclosure of accounting policies and definition of accounting estimates
- Amendments to MFRS 112 'Deferred Tax related to Assets and Liabilities arising from a Single Transaction'

Effective for annual periods beginning on or after 1 January 2024

- Classification of Liabilities as Current or Non-current (Amendments to MFRS 101) ('the 2020 amendments')
- Non-current Liabilities with Covenants (Amendments to MFRS 101) ('the 2022 amendments')

The accounting pronouncements that are not yet effective are not expected to have any significant impact on the financial statements of the Group and the Foundation.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

B DONATIONS AND RESEARCH GRANTS

Donations and research grants are recognised as income when the Foundation's right to receive payment is established.

C OTHER INCOME

Interest income is recognised on a time proportion basis, taking into account the principal outstanding and the effective interest rate over the period to maturity, when it is determined that such income will accrue to the Foundation.

Income from advisory and consultancy service is recognised when the services are provided.

D SUBSIDIARY

Subsidiary is an entity over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Inter-company transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset.

Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

In the Foundations' separate financial statements, investments in subsidiary is carried at cost less accumulated impairment losses

E PROPERTY, PLANT AND EQUIPMENT

Plant and equipment are stated at historical cost less accumulated depreciation and impairment losses. The cost of an item of plant and equipment initially recognised includes its purchase price, import duties, non-refundable purchase taxes and any cost that is directly attributable in bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Cost also includes borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Foundation and the cost of the item can be measured reliably. The carrying amount of the replaced part is de-recognised. All other repairs and maintenance are recognised as expenses in profit or loss during the period in which they are incurred.

Gains or losses on disposals are determined by comparing proceeds with carrying amount and are included in profit or loss.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

E PROPERTY, PLANT AND EQUIPMENT (continued)

Plant and equipment are depreciated on the straight line method to allocate the costs to their residual values over their estimated useful lives, summarised as follows:

<u>Property, plant and equipment</u>	<u>Estimated useful lives</u>
Laboratory equipment	10 years
Renovations	4 years
Computers	3 years
Office equipment	10 years

Residual values and useful lives of assets are reviewed, and adjusted if appropriate, at the end of each reporting period. At the end of the reporting period, the Foundation assesses whether there is any indication of impairment. If such indications exist, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. A write down is made if the carrying amount exceeds the recoverable amount. See accounting policy F on impairment of non-financial assets.

F IMPAIRMENT OF NON-FINANCIAL ASSETS

Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the carrying amount of the asset exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value-in-use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting date.

The impairment loss is charged to the income and expenditure statements and any subsequent increase in recoverable amount is recognised in the income and expenditure statements.

G GOVERNMENT GRANTS

Grants from the government are recognised at their fair values when there is a reasonable assurance that the grant will be received and the Foundation will comply with their attached conditions.

Government grants relating to costs are deferred and recognised in the income and expenditure statements over the period necessary to match them with the costs they are intended to compensate.

Government grants relating to the purchase of assets are included in liabilities as deferred income and are credited to the income and expenditure statements on a straight line basis over the expected useful lives of the related assets.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

H CASH AND CASH EQUIVALENTS

For the purpose of the statement of cash flows, cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. Cash and cash equivalents comprise cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of 3 months or less that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

I EMPLOYEE BENEFITS

(a) Short term benefits

Wages, salaries, bonuses and social security contributions are recognised as an expense in the period in which the associated services are rendered by employees of the Foundation.

(b) Defined contribution plans

The Foundation's contributions to defined contribution plans are charged to profit or loss in the period to which they relate. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

J FINANCIAL ASSETS

(i) Classification

The Foundation classifies its financial assets as those to be measured at amortised cost.

(ii) Recognition and initial measurement

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Foundation commit to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Foundation have transferred substantially all the risks and rewards of ownership.

(iii) Subsequent measurement

• **Debt instruments at amortised cost**

After initial recognition, financial assets that are held for collection of contractual cash flows where those cash flows represent solely payment of principal and interest are measured at amortised cost using the effective interest method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in 'other operating income' or 'other operating expenses'.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

J FINANCIAL ASSETS (continued)

(iv) Impairment

The Foundation assess on a forward looking basis the expected credit loss ('ECL') associated with its debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

The financial instruments held by the Foundation that are subject to the ECL model are donations receivable and other receivables. While cash and bank balances are also subject to the impairment requirements of MFRS 9, the identified impairment loss was immaterial.

ECL represent a probability-weighted estimate of the difference between present value of cash flows according to contract and present value of cash flows the Foundation expect to receive, over the remaining life of the financial instrument.

The measurement of ECL reflects:

- an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes;
- the time value of money; and
- reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future economic conditions.

General 3-stage approach for donation receivables and other receivables

At each reporting date, the Foundation measure ECL through loss allowance at an amount equal to 12 month ECL if credit risk on a financial instrument or a group of financial instruments has not increased significantly since initial recognition. For all other financial instruments, a loss allowance at an amount equal to lifetime ECL is required.

(v) Significant increase in credit risk

The Foundation consider the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Foundation compare the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition. It considers available reasonable and supportable forward-looking information.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

J FINANCIAL ASSETS (CONTINUED)

(vi) Definition of default and credit-impaired financial assets

The Foundation define a financial instrument as default, which is fully aligned with the definition of credit-impaired, when it meets one or more of the following criteria:

- When the counterparty fails to make contractual payment when they fall due.
- it is becoming probable that the debtor will enter bankruptcy or other financial reorganise
- the debtor is insolvent

(vii) Write-off

Financial assets are written off when the Foundation have exhausted all practical recovery efforts and have concluded that there is no reasonable expectation of recovery. Indicator of no reasonable expectation of recovery include failure of a debtor to engage in a repayment plan with the Foundation. The Foundation may write-off financial assets that are still subject to enforcement activity.

(viii) De-recognition

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Foundation have transferred substantially all the risks and rewards of ownership.

K FINANCIAL LIABILITIES

A financial liability is any liability that is a contractual obligation to deliver cash or another financial asset to another enterprise, or to exchange financial instruments in another enterprise under conditions that are potentially unfavourable.

Financial liabilities are recognised in the statements of financial position when, and only when, the Foundation become a party to the contractual provisions of the financial instrument.

The Foundation classify the financial liabilities as other financial liabilities. The classification depends on the nature of the liabilities and the purpose for which the financial liabilities were incurred. Management determines the classification at initial recognition.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

K FINANCIAL LIABILITIES (CONTINUED)

Other financial liabilities

Other financial liabilities comprise 'payables' (Note 12).

When other financial liabilities are recognised initially, they are measured at fair value plus directly attributable transaction costs.

Subsequent to the initial recognition, other financial liabilities are measured at amortised cost using the effective interest method. Gains and losses are recognised in the income and expenditure statements when the other financial liabilities are derecognised, and through the amortisation process.

Financial liabilities are derecognised when the obligation specified in the contract is discharged, cancelled or expired.

Financial liabilities are classified as current liabilities for those having maturity dates of less than twelve months after the reporting date, otherwise, the balance is classified as non-current.

L OFFSETTING FINANCIAL INSTRUMENTS

Financial assets and liabilities are offset and the net amount is presented in the statements of financial position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

M LEASES

The Foundation as a lessee

Leases are recognised as a right-of-use ("ROU") asset and a corresponding liability at the date at which the leased asset is available for use by the Foundation.

Contracts may contain both lease and non-lease components. The Foundation allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of properties for which the Foundation is a lessee, it has elected the practical expedient provided in MFRS 16 not to separate lease and non-lease components. Both components are accounted for as a single lease component and payments for both components are included in the measurement of lease liability.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

M LEASES (CONTINUED)

The Foundation as a lessee (continued)

(a) Lease term

In determining the lease term, the Foundation considers all facts and circumstances that create an economic incentive to exercise an extension option, or not to exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not to be terminated).

The Foundation reassesses the lease term upon the occurrence of a significant event or change in circumstances that is within the control of the Foundation and affects whether the Foundation is reasonably certain to exercise an option not previously included in the determination of lease term, or not to exercise an option previously included in the determination of lease term. A revision in lease term results in remeasurement of the lease liabilities (refer to (d) below).

(b) ROU assets

ROU assets are initially measured at cost comprising the following:

- The amount of the initial measurement of lease liability;
- Any lease payments made at or before the commencement date less any lease incentive received;
- Any initial direct costs; and
- Decommissioning or restoration costs.

The ROU asset is depreciated over the shorter of the right-of-use asset's useful life and the lease term on a straight-line basis, as follows:

<u>ROU asset</u>	<u>Lease term</u>
Premise	1 year

The ROU assets are adjusted for any remeasurement of the lease liability.

At each statement of financial position date, the Foundation assess whether there is any indication of impairment. If such an indication exists, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

M LEASES (CONTINUED)

The Foundation as a lessee (continued)

(c) Lease liabilities

Lease liabilities are initially measured at the present value of the lease payments that are not paid at that date. The lease payments include the following:

- Fixed payments (including in-substance fixed payments), less any lease incentive receivable;
- Variable lease payments that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- Amounts expected to be payable by the Foundation under residual value guarantees;
- The exercise price of a purchase and extension options if the Foundation is reasonably certain to exercise that option; and
- Payments of penalties for terminating the lease, if the lease term reflects the Foundation exercising that option.

Lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Foundation, the lessee's incremental borrowing rate is used. This is the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the ROU in a similar economic environment with similar term, security and conditions.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Variable lease payments that depend on sales are recognised in profit or loss in the period in which the condition that triggers those payments occurs.

The Foundation presents the lease liabilities as a separate line item in the statement of financial position. Interest expense on the lease liability is presented within the finance cost in the statement of profit or loss.

(d) Reassessment of lease liabilities

The Foundation is also exposed to potential future increases in variable lease payments that depend on an index or rate, which are not included in the lease liability until they take effect. When adjustments to lease payments based on an index or rate take effect, the lease liability is remeasured and adjusted against the ROU assets.

(e) Short-term leases and leases of low-value assets

Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture. Payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognised on a straight-line basis as an expense in profit or loss.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

N CONTINGENT ASSETS AND CONTINGENT LIABILITIES

The Foundation do not recognise a contingent asset and liability but discloses its existence in the financial statements. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Foundation or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in the extremely rare circumstance where there is a liability that cannot be recognised because it cannot be measured reliably. However, contingent liabilities do not include financial guarantee contracts.

A contingent asset is a possible asset that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Foundation. The Foundation do not recognise contingent assets but discloses its existence where inflows or economic benefits are probable, but not virtually certain.

3 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Foundation are exposed to financial risks arising from their operations and the use of financial instruments. The key financial risks include credit risk and liquidity risk.

The following sections provide details regarding the Foundation's exposure to the above-mentioned financial risks and the objectives, policies and processes for the management of these risks.

(a) Credit risk

Credit risk is the risk of loss that may arise on outstanding financial instruments should a counterparty default on its obligations. At the reporting date, the Foundation's maximum exposure to credit risk is represented by the carrying amount of each class of financial assets recognised in the statements of financial position.

Measurement of Expected Credit Loss ("ECL")

General 3-stage approach for donation receivables and other receivables

Donations receivables and other receivables are considered to have low credit risk, and thus the impairment provision during the period was limited to 12 months expected credit loss. They are considered to be low credit risk as they have a low risk of default and the counterparties have strong capacity to meet their contractual cash flow obligations in the near term.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

3 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

(a) Credit risk (continued)

General 3-stage approach for donation receivables and other receivables (continued)

Cash and cash equivalents and deposits of the Foundation are placed with credit worthy financial institutions and the risks arising therefrom are minimised in view of the financial strength of these financial institutions.

(b) Liquidity risk

Liquidity risk is the risk that the Foundation will encounter difficulty in meeting financial obligations due to shortage of funds. The Foundation's exposure to liquidity risk arises primarily from mismatch of the maturity of the financial assets and liabilities.

The Foundation adopt prudent liquidity risk management by maintaining sufficient cash resources and having available funding through donors. The Foundation's operations are financed mainly through donations and research grants received.

The table below summarise the maturity profile and contractual undiscounted cash flows based on the remaining maturity periods at the statement of financial position date:

<u>Group</u>	<u>Less than a year</u> RM	<u>Between 1 – 2 years</u> RM	<u>Between 2 – 5 years</u> RM	<u>Over 5 years</u> RM	<u>Total</u> RM
<u>At 31 December 2022</u>					
Payables	786,122	-	-	-	786,122
Lease liabilities	16,673	-	-	-	16,673
	<u>802,795</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>802,795</u>
<u>At 31 December 2021</u>					
Payables	21,747	-	-	-	21,747
Lease liabilities	100,035	16,673	-	-	116,708
	<u>121,782</u>	<u>16,673</u>	<u>-</u>	<u>-</u>	<u>138,455</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

3 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

(b) Liquidity risk (continued)

	<u>Less than a year</u> RM	<u>Between 1 – 2 years</u> RM	<u>Between 2 – 5 years</u> RM	<u>Over 5 years</u> RM	<u>Total</u> RM
<u>Foundation</u>					
<u>At 31 December 2022</u>					
Payables	784,072	-	-	-	784,072
Lease liabilities	16,673	-	-	-	16,673
Amount due to a subsidiary	100	-	-	-	100
	<u>800,845</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>800,845</u>
<u>At 31 December 2021</u>					
Payables	21,747	-	-	-	21,747
Lease liabilities	100,035	16,673	-	-	116,708
Amount due to a subsidiary	100	-	-	-	100
	<u>121,882</u>	<u>16,673</u>	<u>-</u>	<u>-</u>	<u>138,555</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)**

4 STAFF COSTS

	<u>Group and Foundation</u>	
	<u>2022</u>	<u>2021</u>
	RM	RM
Salaries, wages and overtime	4,900,504	4,131,320
Defined contribution plan	567,680	510,164
Other employee benefits	226,803	153,841
	<u>5,694,987</u>	<u>4,795,325</u>

5 TAXATION

The Foundation has made no provision as it is a charitable institution which is exempted from tax by virtue of Section 127 (1) of the Income Tax Act, 1967 (Paragraph 13(1)(a) of Schedule 6).

The subsidiary is entitled to tax exemption by virtue of Section 127 (3A) of the Income Tax Act, 1967 for a period of 5 years beginning from Year of Assessment of 2021 to 2025.

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

6 **PROPERTY, PLANT AND EQUIPMENT**

	<u>Laboratory equipment</u> RM	<u>Renovations</u> RM	<u>Computers</u> RM	<u>Office equipment</u> RM	<u>Total</u> RM
<u>Group and Foundation</u>					
<u>2022</u>					
<u>Cost</u>					
At 1 January 2022	9,211,930	709,000	860,686	155,435	10,937,051
Additions	379,448	1,912,460	66,126	16,900	2,374,934
Disposals	(1,557,342)	-	(133,754)	(79,811)	(1,770,907)
At 31 December 2022	<u>8,034,036</u>	<u>2,621,460</u>	<u>793,058</u>	<u>92,524</u>	<u>11,541,078</u>
<u>Accumulated depreciation</u>					
At 1 January 2022	7,914,841	627,653	680,033	121,520	9,344,047
Depreciation charge for the financial year	354,408	121,042	101,665	8,304	585,419
Disposals	(1,505,462)	-	(133,748)	(72,048)	(1,711,258)
At 31 December 2022	<u>6,763,787</u>	<u>748,695</u>	<u>647,950</u>	<u>57,776</u>	<u>8,218,208</u>
<u>Net book value</u>					
At 31 December 2022	<u><u>1,270,249</u></u>	<u><u>1,872,765</u></u>	<u><u>145,108</u></u>	<u><u>34,748</u></u>	<u><u>3,322,870</u></u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

6 **PROPERTY, PLANT AND EQUIPMENT (CONTINUED)**

	<u>Laboratory equipment</u> RM	<u>Renovations</u> RM	<u>Computers</u> RM	<u>Office equipment</u> RM	<u>Total</u> RM
<u>Group and Foundation</u>					
<u>2021</u>					
<u>Cost</u>					
At 1 January 2021	9,209,630	829,225	908,598	158,142	11,105,595
Additions	2,300	62,412	96,915	-	161,627
Write off	-	(182,637)	(27,767)	(2,705)	(213,109)
Disposals	-	-	(117,060)	(2)	(117,062)
At 31 December 2021	<u>9,211,930</u>	<u>709,000</u>	<u>860,686</u>	<u>155,435</u>	<u>10,937,051</u>
<u>Accumulated depreciation</u>					
At 1 January 2021	7,541,849	794,740	721,917	111,657	9,170,164
Depreciation charge for the financial year	372,991	15,550	102,943	11,104	502,588
Write off	-	(182,637)	(27,767)	(1,239)	(211,643)
Disposals	-	-	(117,060)	(2)	(117,062)
At 31 December 2021	<u>7,914,841</u>	<u>627,653</u>	<u>680,033</u>	<u>121,520</u>	<u>9,344,047</u>
<u>Net book value</u>					
At 31 December 2021	<u>1,297,089</u>	<u>81,347</u>	<u>180,653</u>	<u>33,915</u>	<u>1,593,004</u>

Purchase of property, plant and equipment

	<u>Group and Foundation</u>	
	<u>2022</u> RM	<u>2021</u> RM
Aggregate cost of property, plant and equipment purchased during the financial year	2,374,934	161,627
Unpaid balances in payables (Note 12)	(537,203)	-
Total cash paid during the financial year	<u>1,837,731</u>	<u>161,627</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

7 RIGHT-OF-USE ASSET

	<u>Group and Foundation</u>
<u>2022</u>	RM
<u>Cost</u>	
At 1 January 2022 / 31 December 2022	297,741
<u>Accumulated depreciation</u>	
At 1 January 2022	192,355
Depreciation charge during the financial year	90,330
At 31 December 2022	<u>282,685</u>
<u>Net book value</u>	
At 31 December 2022	<u>15,056</u>
<u>2021</u>	
<u>Cost</u>	
At 1 January 2021	223,601
Lease modification	74,140
At 31 December 2021	<u>297,741</u>
<u>Accumulated depreciation</u>	
At 1 January 2021	98,446
Depreciation charge during the financial year	93,909
At 31 December 2021	<u>192,355</u>
<u>Net book value</u>	
At 31 December 2021	<u>105,386</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

8 INVESTMENT IN A SUBSIDIARY – AT COST

	<u>Foundation</u>	
	<u>2022</u>	<u>2021</u>
	RM	RM
<u>Unquoted shares – at cost</u>		
At 1 January	100	-
Investment during the financial year	-	100
At 31 December	<u>100</u>	<u>100</u>

Information of the subsidiary is as follows:

<u>Name of company</u>	<u>Effective equity interest</u>		<u>Principal activities</u>	<u>Place of incorporation</u>	<u>Incorporationdate</u>
	<u>2022</u>	<u>2021</u>			
CRMY Technologies Sdn. Bhd. *	100%	100%	Leasing intellectual property, research and development on medical sciences	Malaysia	24 September 2021

* The Company has not commenced operations since the date of incorporation.

9 RECEIVABLES

	<u>Group and Foundation</u>	
	<u>2022</u>	<u>2021</u>
	RM	RM
Donations receivable	1,622,342	79,334
Deposits	32,463	32,463
Interest receivable	173,788	125,162
Prepayment	621,567	308,754
GST input	8,796	335,190
	<u>2,458,956</u>	<u>880,903</u>
Loss allowance: GST receivable	(8,796)	(221,358)
	<u>2,450,160</u>	<u>659,545</u>

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

9 RECEIVABLES (CONTINUED)

GST receivables using general 3 stage approach

(i) Reconciliation of loss allowance

The loss allowance for donation receivables as at 31 December 2022 reconciles to the opening loss allowance for that provision as follows:

	<u>Performing</u> RM	<u>Under- performing</u> RM	<u>Non- performing</u> RM	<u>Total</u> RM
Opening loss allowance as at 1 January 2021	-	-	-	-
Loss allowance charged during the financial year	-	-	221,358	221,358
Loss allowance as at 31 December 2021	-	-	221,358	221,358
Reversal of loss allowance	-	-	(212,562)	(212,562)
Closing loss allowance as at 31 December 2022	-	-	8,796	8,796

The reversal of loss allowance during the financial year was in respect to receipt of GST receivable from the authority.

10 DEPOSITS, CASH AND BANK BALANCES

	<u>Group</u>		<u>Foundation</u>	
	<u>2022</u> RM	<u>2021</u> RM	<u>2022</u> RM	<u>2021</u> RM
Fixed deposit with a licensed bank	18,700,000	15,600,000	18,700,000	15,600,000
Bank balances	1,128,699	227,178	1,127,985	227,178
Cash in hand	1,200	1,500	1,200	1,500
	<u>19,829,899</u>	<u>15,828,678</u>	<u>19,829,185</u>	<u>15,828,678</u>
Less: Fixed deposit with licensed bank more than 3 months	<u>(16,900,000)</u>	<u>(14,880,000)</u>	<u>(16,900,000)</u>	<u>(14,880,000)</u>
	<u>2,929,899</u>	<u>948,678</u>	<u>2,929,185</u>	<u>948,678</u>

The deposits with licensed bank carry fix interest rates ranging from 1.8% to 3.7% (2021: 1.70% to 2.15%) per annum as at the reporting date and have maturity periods ranging from 2 to 12 months (2021: 1 to 12 months).

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

11 LEASE LIABILITY

	<u>Group and Foundation</u>	
	<u>2022</u> RM	<u>2021</u> RM
At 1 January	114,017	132,848
Lease modification	-	74,140
Interest accretion	2,613	5,666
Payment of lease liabilities	(100,035)	(98,637)
	<u>16,595</u>	<u>114,017</u>
At 31 December	<u>16,595</u>	<u>114,017</u>
Non-current	-	13,982
Current	16,595	100,035
	<u>16,595</u>	<u>114,017</u>

Total cash outflow for leases of the Group and Foundation are as follows:

	<u>Group and Foundation</u>	
	<u>2022</u> RM	<u>2021</u> RM
Payment of lease liabilities	100,035	98,637
Rental of other equipment (service contract, low value assets and short term lease)	41,305	34,778
	<u>141,340</u>	<u>133,415</u>

12 PAYABLES

	<u>Group</u>		<u>Foundation</u>	
	<u>2022</u> RM	<u>2021</u> RM	<u>2022</u> RM	<u>2021</u> RM
Accruals	12,450	3,360	10,400	3,360
Other payables	236,469	18,387	236,469	18,387
Unpaid balances for acquisition of Property, plant and equipment (Note 6)	537,203	-	537,203	-
	<u>786,122</u>	<u>21,747</u>	<u>784,072</u>	<u>21,747</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022 (CONTINUED)

13 FINANCIAL INSTRUMENTS

The table below provides an analysis of financial instruments categorised as follows:

	<u>Group</u>		<u>Foundation</u>	
	<u>2022</u>	<u>2021</u>	<u>2022</u>	<u>2021</u>
	RM	RM	RM	RM
<u>Financial assets classified as amortised cost</u>				
Amount due from a subsidiary	-	-	6,325	-
Receivables	1,828,593	236,959	1,828,593	236,959
Deposits, cash and bank balances	19,829,899	15,828,678	19,829,185	15,828,678
	<u>21,658,492</u>	<u>16,065,637</u>	<u>21,664,103</u>	<u>16,065,637</u>
<u>Financial liabilities classified as amortised cost</u>				
Lease liability	16,595	114,017	16,595	114,017
Payables	786,122	21,747	784,072	21,747
Amount due to a subsidiary	-	-	100	100
	<u>802,717</u>	<u>135,764</u>	<u>800,767</u>	<u>135,864</u>

14 AUTHORISATION FOR ISSUE OF FINANCIAL STATEMENTS

The financial statements were authorised for issue by Trustees on 8 June 2023.

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**STATEMENT BY TRUSTEES PURSUANT TO
SECTION 251(2) OF THE COMPANIES ACT 2016**

We, Toh Puan Dato' Seri Hajjah Dr Aishah Ong and Alan Hamzah Sendut, being Trustees of Cancer Research Malaysia, do hereby state that, in the opinion of the Trustees, the financial statements set out on pages 5 to 31 are drawn up so as to give a true and fair view of the financial position of the Group and of the Foundation as at 31 December 2022 and financial performance of the Group and the Foundation for the financial year ended on that date in accordance with the Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

Signed on behalf of the Board of Trustees in accordance with the resolution of the Board of Trustees dated 8 June 2023.

TOH PUAN DATO' SERI HAJJAH
DR AISHAH ONG

TRUSTEE

ALAN HAMZAH SENDUT

TRUSTEE

**STATUTORY DECLARATION PURSUANT TO
SECTION 251(1) OF THE COMPANIES ACT 2016**

I, Khoo Boo Teik, the Chief Executive Officer primarily responsible for the financial management of Cancer Research Malaysia, do solemnly and sincerely declare that the financial statements set out on pages 5 to 31 are, in my opinion, correct and I make this solemn declaration conscientiously believing the same to be true, and by virtue of the provisions of the Statutory Declarations Act 1960.

KHOO BOO TEIK

Petaling Jaya
Selangor Darul Ehsan

Subscribed and solemnly declared by the above named Khoo Boo Teik at Selangor Darul Ehsan on 8 June 2023.

Before me,

COMMISSIONER FOR OATHS



NO. 5-2, JALAN PJS 11/28,
BANDAR SUNWAY,
46150 PETALING JAYA,
SELANGOR



**INDEPENDENT AUDITORS' REPORT
TO THE TRUSTEES OF CANCER RESEARCH MALAYSIA**
(Company Limited by Guarantee)
(Incorporated in Malaysia)
Registration No. 200001007481 (510087-M)

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

Our opinion

In our opinion, the financial statements of Cancer Research Malaysia (“the Foundation”) and its subsidiary (“the Group”) give a true and fair view of the financial position of the Group and of the Foundation as at 31 December 2022, and of their financial performance and their cash flows for the financial year then ended in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

What we have audited

We have audited the financial statements of the Group and of the Foundation, which comprise the statements of financial position as at 31 December 2022 of the Group and of the Foundation, and the income and expenditure statements, statements of changes in general funds and statements of cash flows of the Group and of the Foundation for the financial year then ended, and notes to the financial statements, including a summary of significant accounting policies, as set out on pages 5 to 31.

Basis for opinion

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing. Our responsibilities under those standards are further described in the “Auditors’ responsibilities for the audit of the financial statements” section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence and other ethical responsibilities

We are independent of the Group and of the Foundation in accordance with the By-Laws (on Professional Ethics, Conduct and Practice) of the Malaysian Institute of Accountants (“By-Laws”) and the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (including International Independence Standards) (“IESBA Code”), and we have fulfilled our other ethical responsibilities in accordance with the By-Laws and the IESBA Code.

Information other than the financial statements and auditors’ report thereon

The Trustees of the Foundation are responsible for the other information. The other information comprises the Trustees’ Report, but does not include the financial statements of the Group and of the Foundation and our auditors’ report thereon.

*PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146), Chartered Accountants, Level 10, Menara TH 1 Sentral, Jalan Rakyat, Kuala Lumpur Sentral, P.O. Box 10192, 50706 Kuala Lumpur, Malaysia
T: +60 (3) 2173 1188, F: +60 (3) 2173 1288, www.pwc.com/my*



**INDEPENDENT AUDITORS' REPORT
TO THE TRUSTEES OF CANCER RESEARCH MALAYSIA (CONTINUED)**
(Company Limited by Guarantee)
(Incorporated in Malaysia)
Registration No. 200001007481 (510087-M)

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

Our opinion on the financial statements of the Group and of the Foundation does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Group and of the Foundation, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements of the Group and of the Foundation or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Trustees for the financial statements

The Trustees of the Foundation are responsible for the preparation of the financial statements of the Group and of the Foundation that give a true and fair view in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia. The Trustees are also responsible for such internal control as the Trustees determine is necessary to enable the preparation of financial statements of the Group and of the Foundation that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Group and of the Foundation, the Trustees are responsible for assessing the Group's and the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Foundation or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements of the Group and of the Foundation as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



**INDEPENDENT AUDITORS' REPORT
TO THE TRUSTEES OF CANCER RESEARCH MALAYSIA (CONTINUED)**
(Company Limited by Guarantee)
(Incorporated in Malaysia)
Registration No. 200001007481 (510087-M)

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

As part of an audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- (a) Identify and assess the risks of material misstatement of the financial statements of the Group and of the Foundation, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and of the Foundation's internal control.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- (d) Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's or on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Group and of the Foundation or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group or the Foundation to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the financial statements of the Group and of the Foundation, including the disclosures, and whether the financial statements of the Group and of the Foundation represent the underlying transactions and events in a manner that achieves fair presentation.
- (f) Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the financial statements of the Group. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.



**INDEPENDENT AUDITORS' REPORT
TO THE TRUSTEES OF CANCER RESEARCH MALAYSIA (CONTINUED)**
(Company Limited by Guarantee)
(Incorporated in Malaysia)
Registration No. 200001007481 (510087-M)


REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

We communicate with the Trustees regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

OTHER MATTERS

This report is made solely to the Trustees of the Foundation, as a body, in accordance with Section 266 of the Companies Act 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report.


PRICEWATERHOUSECOOPERS PLT
LLP0014401-LCA & AF 1146
Chartered Accountants


MAHESH A/LAKAMESH
03428/04/2025 J
Chartered Accountant

Kuala Lumpur
8 June 2023